4.7 Meeting Abstract

Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of panitumumab plus chemotherapy versus chemotherapy or chemotherapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC

Journal

ANNALS OF ONCOLOGY
Volume 27, Issue -, Pages -

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdw363.37

Keywords

-

Categories

Funding

  1. Amgen Ltd

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available